Resmed agreed to acquire Noctrix Health for $340 million, adding a wearable neuromodulation option for restless legs syndrome to its sleep health portfolio. Noctrix’s Nidra device aims to treat RLS without disrupting sleep, positioning the company against pharmacologic and other device approaches. Noctrix estimates the addressable RLS market is large, citing prevalence near 7% of adults globally and roughly 17 million U.S. adults. Resmed’s move suggests continued growth of non-drug sleep interventions as major device ecosystems consolidate. The acquisition also underscores how sleep platforms increasingly serve as a hub for adjacent neurological and symptom-driven conditions rather than remaining limited to traditional positive airway pressure categories.